← Back to all signals
RESEARCH PAPER ANALYSIS

Efficacy and safety of JMT103 in patients with unresectable or surgically-challenging giant cell tumor of bone: a multicenter, phase Ib/II study.

AI interpretation is pending for this paper.

Open original publication →
PMID39500883
JournalNature communications
Publication Date2024-11-05
Ingested2026-08-02 12:02 AM
EXECUTIVE SUMMARY

What the AI sees

Not AI summarized yet.

WHY IT MATTERS

Research significance

Pending deeper interpretation.

ABSTRACT

Source abstract

This was a multicenter, single-arm, open-label, phase Ib/II study (NCT04255576), aimed to evaluate the efficacy and safety of JMT103 in patients with unresectable or surgically-challenging giant cell tumor of bone (GCTB). JMT103 (2 mg/kg) was administered subcutaneously every four weeks, with loading doses on days 8 and 15. The primary endpoint was the objective tumor response rate (OTR) based on best response, defined as the proportion of patients who achieved elimination of at least 90% of the giant cells or radiologic complete or partial response per the modified Inverse Choi density/size (mICDS) or modified European Organization for Research and Treatment of Cancer (mEORTC) within 12 weeks. Secondary endpoints included objective response rate (ORR) per mICDS and mEORTC, and safety. A total of 139 patients were enrolled, and 135 were analyzed for efficacy. OTR, determined by the independent review committee (IRC) was 93.3% (95% CI 87.7-96.9). Treatment-related adverse events occurred in 90 (64.7%) patients, with hypophosphatemia and hypocalcemia being the most common. No serious treatment-related adverse events were observed. Thus, JMT103 demonstrates potential as a therapeutic option for GCTB.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 Plasma Cell Gingivitis With Cheilitis in an Adolescent: A Case Report. Cureus 51.1 2 Efgartigimod as a salvage therapy for anti-NMDAR encephalitis patients after first-line treatment failure: a case series. Frontiers in neurology 65.18 3 Successful treatment of refractory classic juvenile pityriasis rubra pilaris with adalimumab in a 4-year-old girl: a case report. Frontiers in immunology 67.0 4 Clinical spectrum and survival outcomes of malignancies in pediatric patients with inborn errors of immunity. Frontiers in immunology 65.82 5 Therapy-related acute myeloid leukemia with 24-month latency after CD19 CAR-T cell therapy in relapsed/refractory diffuse large B-cell lymphoma: a case report. Frontiers in medicine 63.86 6 HPV52 predominates in cervical infections and precancerous lesions in Chongqing, China: a 6-year study linking genotypes to vaginal microecology. Frontiers in public health 61.9 7 Report from the National Pediatric Cancer Foundation - infantile glioma and other non-embryonal central nervous system tumors: evolving molecular advances and current treatment landscape. Frontiers in oncology 68.34 8 Targeted immunotherapies for anaplastic lymphoma kinase-positive pediatric tumors: current advances and future perspectives. Frontiers in immunology 87.5 9 The real-world practice of fertility preservation for patients with epithelial ovarian cancer in Asian regions. Journal of gynecologic oncology 67.2 10 Multiple congenital dermal sinus tracts: a case-based review involving a unique triple-tract configuration that challenges current embryological concepts. Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 49.9 11 Natural products mediate ferroptosis and immune microenvironment-linked sensitization in osteosarcoma: from chemotherapy resistance to combined therapeutic transformation. Molecular diversity 71.38 12 Age-associated epigenomic heterogeneity in papillary tumors of the pineal region: a multicenter YoungNOA investigation. Acta neuropathologica communications 66.6 13 Pediatrics supratentorial intraventricular atypical teratoid/rhabdoid tumors: a case report and a systematic review of the literature. European journal of pediatrics 77.1 14 Cranial pathologies in Noonan syndrome: clinical implications for pre-growth hormone neuroimaging. European journal of pediatrics 61.4 15 Narciclasine reduces proliferation and migration of neuroblastoma cells and decreases FAK/PI3K pathway activation. Medical oncology (Northwood, London, England) 43.0 16 Balancing safe resection and spinal stability in osteoblastoma and osteoid osteoma: a retrospective study. European journal of orthopaedic surgery & traumatology : orthopedie traumatologie 67.4 17 Scaling up symptom screening for routine use in pediatric oncology: provincial implementation. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 61.6 18 Extent of resection and craniopharyngioma recurrence: a volumetric analysis. Journal of neuro-oncology 66.1 19 Fertility in breast cancer survivorship: a scoping review. Journal of cancer survivorship : research and practice 81.0 20 Clinical practice guideline for psoriasis management in Latin America. Anais brasileiros de dermatologia 76.5 21 Constrained Choices and Meaning-Making: A Qualitative Study of Caregivers of Children With Hematologic Malignancies. Psycho-oncology 59.6 22 Timely Surgical Approaches for Pediatric Epilepsy Resistant to Medication. Journal of surgery and research 64.0 23 The Journey with paediatric cancer: reflections on its impact on patients and their families. The Pan African medical journal 56.0 24 Pars plana vitrectomy in uveitis of diverse etiologies: indications and surgical outcomes. BMC ophthalmology 63.5 25 Persistent Oropharyngeal Hemangioma Causing Progressive Upper Airway Compromise: Diagnostic and Therapeutic Challenges. Cureus 61.64 26 Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment, and follow-up of patients with hepatocellular carcinoma. ESMO open 71.84 27 Life Saving Hepatic Resections in Ruptured Pediatric Hepatoblastoma - a Report of 3 Cases. Indian journal of surgical oncology 63.6 28 Development and Internal Validation of the SPR-HCC Score System: A Prognostic Tool for Survival Prediction in Hepatocellular Carcinoma in a Resource-Limited Setting. Asian Pacific journal of cancer prevention : APJCP 72.02 29 Retinoblastoma Incidence in Saudi Arabia: A 20-Year Analysis. Asian Pacific journal of cancer prevention : APJCP 57.5 30 Systemic Immune Inflammation Index as High-Risk Retinoblastoma Survival Predictor. Asian Pacific journal of cancer prevention : APJCP 63.12 31 Predictors of Cervical Cancer Screening Uptake Among Women of Reproductive Age in Indonesia: A Nationwide Cross-Sectional Study Based on the 2023 Indonesian Health Survey. Asian Pacific journal of cancer prevention : APJCP 67.5 32 Effects of estetrol/drospirenone vs drospirenone-only on thrombin generation in women with polycystic ovary syndrome: a randomized, double-blind, controlled trial. Research and practice in thrombosis and haemostasis 77.6
PATIENT-FRIENDLY SUMMARY

Efficacy and safety of JMT103 in patients with unresectable or surgically-challenging giant cell tumor of bone: a multicenter, phase Ib/II study.

For education only—not personal medical advice.

Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic